Bear of the Day: PetMed Express (PETS)

07.03.25 10:30 Uhr

Werte in diesem Artikel
Aktien

2,96 EUR -0,07 EUR -2,21%

Indizes

15.599,5 PKT -3,8 PKT -0,02%

PetMed Express (PETS) is built around an appealing concept—capitalizing on the rapidly growing pet ownership trend by offering pet medications and health products through an online platform. In theory, the company is well positioned in a market where pet spending continues to rise. However, its execution has failed to keep pace with industry growth, and the stock’s sharp decline over the past two years reflects a business struggling to maintain momentum.Sales and earnings have been on a steady decline, and analysts have consistently lowered earnings estimates, signaling deteriorating fundamentals. Despite this weakness, the stock still trades at a surprisingly high relative valuation, making it an even less attractive option for investors. Without a clear turnaround in revenue growth and profitability, PETS remains a stock to avoid until its fundamentals show signs of meaningful improvement.Image Source: Zacks Investment ResearchPETS Struggles with Falling Sales and Earnings Downgrades PetMed Express has been caught in a multi-year sales decline, and the outlook remains bleak. Annual revenue has been shrinking for the last three years, and analysts expect this trend to continue. Sales are projected to decline by 18.6% this year and another 6.8% next year, indicating persistent weakness in the company’s ability to generate growth.Earnings expectations have also been consistently revised lower, further underscoring PetMed’s deteriorating fundamentals. In just the past month, analysts have cut their estimates for the current quarter by 20%, while full-year 2025 earnings forecasts have been slashed by 20.8%. The company now holds a Zacks Rank #5 (Strong Sell) rating, reflecting its unfavorable earnings trajectory.The outlook for profitability is even more concerning, with earnings projected to plummet by 84% over the next year. With sales momentum fading and margins under pressure, the company faces significant hurdles to reversing its downward trajectory.Image Source: Zacks Investment ResearchPetMed Express Valuation May Still be too HighDespite its ongoing struggles, PetMed Express continues to trade at a surprisingly high valuation. The stock currently carries a one-year forward earnings multiple of 21.1x, which is in line with the broader market. However, given the company's deteriorating fundamentals this valuation appears difficult to justify and could further increase the downside risk in the stock.Image Source: Zacks Investment ResearchShould Investors avoid PETS Stock?With declining sales, shrinking earnings, and ongoing analyst downgrades, PetMed Express faces significant challenges that show no signs of easing. The company’s inability to capitalize on the booming pet care industry raises concerns about its long-term viability, especially as competition intensifies from larger e-commerce players and traditional pet retailers.Despite these headwinds, PETS continues to trade at a valuation that appears too high given its weak fundamentals, making it even less attractive for investors. Until the company can stabilize its business, improve profitability, and regain earnings momentum, there is little reason to take a chance on this struggling stock. For now, PETS remains a stock to avoid, as further downside risk appears likely.Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: PetMed Express und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf PetMed Express

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf PetMed Express

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu PetMed Express Inc.

Wer­bung

Analysen zu PetMed Express Inc.

DatumRatingAnalyst
16.08.2019PetMed Express HoldCraig Hallum
26.05.2010PetMed Express "underperform"Wedbush Morgan Securities Inc.
21.02.2008PetMed Express sellPiper Jaffray & Co.
17.01.2008PetMed Express holdWedbush Morgan Securities Inc.
23.04.2007PetMed Express market performPiper Jaffray
DatumRatingAnalyst
23.01.2007PetMed Express buyRoth Capital
14.09.2006PetMed Express buyWedbush Morgan
06.09.2006PetMed Express market outperformJMP Securities
27.07.2006PetMed Express Kursziel 14 EuroFocus Money
23.03.2006Update PetMed Express Inc.: BuyWedbush Morgan
DatumRatingAnalyst
16.08.2019PetMed Express HoldCraig Hallum
17.01.2008PetMed Express holdWedbush Morgan Securities Inc.
23.04.2007PetMed Express market performPiper Jaffray
24.10.2006Update PetMed Express Inc.: HoldWedbush Morgan
DatumRatingAnalyst
26.05.2010PetMed Express "underperform"Wedbush Morgan Securities Inc.
21.02.2008PetMed Express sellPiper Jaffray & Co.
21.11.2006Update PetMed Express Inc.: UnderperformFirst Albany

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für PetMed Express Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen